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Background: Resistance to tyrosine kinase inhibitors (TKIs) remains a challenge in management of patients with
chronic myeloid leukemia (CML). A better understanding of the BCR-ABL signalling network may lead to better
therapy.
Findings: Here we report the discovery of a novel downstream target of BCR-ABL signalling, PRL-3 (PTP4A3), an
oncogenic tyrosine phosphatase. Analysis of CML cancer cell lines and CML patient samples reveals the
upregulation of PRL-3. Inhibition of BCR-ABL signalling either by Imatinib or by RNAi silencing BCR-ABL reduces
PRL-3 and increases cleavage of PARP. In contrast, the amount of PRL-3 protein remains constant or even increased
in response to Imatinib treatment in drug resistant cells expressing P210 T315I. Finally, analysis with specific shRNA
shows PRL-3 involvement in the proliferation and self-renewal of CML cells.
Conclusions: These data support a role for PRL-3 in BCR-ABL signalling and CML biology and may be a potential
therapeutic target downstream of BCR-ABL in TKI resistant mutant cells.
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Chronic myeloid leukemia (CML) is a hematopoietic stem
cell malignancy with a hallmark cytogenetic abnormality,
i.e., the BCR-ABL fusion oncogene, resulting from the re-
ciprocal translocation of chromosomes 9 and 22 [also
known as Philadelphia (Ph) chromosome] [1]. CML is the
best and most successful disease model for tyrosine kinase
inhibitor (TKI) therapy [2,3]. Unfortunately, acquired re-
sistance can develop during the course of treatment. Ef-
fective therapies that can overcome resistance still remain
a challenge for the clinical management of CML [2,4].
The mechanism of BCR-ABL induced transformation and
signaling transduction networks have been intensively* Correspondence: mdccwj@nus.edu.sg
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reproduction in any medium, provided the orcharacterized over the decades [5-7]. However, new
discoveries related to the BCR-ABL signaling pathway and
mechanisms of TKI resistance continues to emerge, lead-
ing to a better understanding of disease progression and
development of novel therapy [8-10].
Protein-tyrosine phosphatase of regenerating liver 3
(PRL-3, encoded by protein tyrosine phosphatase type IVA
3, PTP4A3) belongs to class I cysteine-based protein tyro-
sine phosphatases (PTPs) with dual-specificity [11-13].
PRL-3 has been identified as a critical player in cancer cell
metastasis, invasion, migration, and tumor angiogenesis
[11,14-16]. The association between elevated PRL-3 and
the development of various human cancers has been
validated in a wide range of solid tumors [11,14,15] and
multiple myeloma [17].
We recently discovered that poly(rC) binding pro-
tein 1 (PCPB1, also known as heterogenous nucleartd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tein through binding 5’-UTR (untranslated region) of
PRL-3 mRNA [18] and showed that PRL-3, acting as a
downstream target of the internal tandem duplication
(ITD) of fms-like tyrosine kinase (FLT3) signaling, was
implicated in FLT3 inhibitor therapy in acute myeloid
leukemia (AML) [19]. Furthermore, PRL-3 also has been
demonstrated as an independent prognostic parameter
for poor overall survival (OS) and event-free survival
(EFS) in AML [20]. Importantly, targeting intracellular
PRL-3 protein suppressed cancer growth [21]. In the
present study, we hypothesize that PRL-3 might be
involved in leukemogenesis of human CML.
Overexprsesion of PRL-3 in CML cell lines and
primary patient samples
A search of the Gene Expression Atlas (http://www.ebi.
ac.uk/gxa/gene/ ENSG00000184489) showed that the
expression level of PRL-3 was highest in CML among
950 human cancer cell lines covering 32 different types
of cancers (Dataset code: E-MTAB-37), suggesting a po-
tential role of PRL-3 in CML pathogenesis (Figure 1A).
To further confirm PRL-3 expression, we examined
PRL-3 protein levels in a panel of CML cell lines and
primary CML BM samples. By immunoblot analysis,
(Additional file 1) we observed strong PRL-3 protein ex-
pression in two human CML cell lines (K562 and KCL-
22, Figure 1B), murine hematopoitic cells expressing
WT and mutant BCR-ABL constructs (P210 WT, P210
T315I, P210 M351T and P210 H396R, Figure 1B middle),Figure 1 PRL-3 expression in CML cell lines and primary CML bone m
expression database (E-MTAB-37). The top five cancers with the highest PR
lung cancer, colorectal cancer, and breast cancer. The complete list of the
(EBI) website. (B) Analysis of PRL-3 protein in normal control (NC) BM samp
BM samples (CML1, 2, 3, 4) by Western blot. β-actin was used as loading coand primary BM samples from CML patients (Figure 1B
right). It is worth noting that PRL-3 is either not expressed
or minimally expressed in bone marrow cells from 3 nor-
mal controls (NC) or parental BaF3 cells (Figure 1B) [19].
Altogether, our data obtained from Western blot analysis
of CML cell lines and primary CML samples, as well as
the analysis of a publicly available gene expression dataset
demonstrated over-expression of PRL-3 in CML.
Imatinib suppressed PRL-3 through inhibition of
STAT pathway
Imatinib blocks the binding of ATP to the BCR-ABL
tyrosine kinase [22,23], and is currently used as the first-
line treatment for CML [2,4]. To establish a connection
between BCR-ABL signalling and PRL-3 expression, we
treated human CML cell lines, K562 and KCL-22 cells
with Imatinib and assessed the expression of PRL-3.
Western blot analysis demonstrated that Imatinib dose-
dependently decreased p-CrkL (a surrogate marker of
BCR-ABL kinase activity), p-STAT3, p-STAT5, as well as
PRL-3 (Figure 2A). Consistent with the effective inhib-
ition of oncogenic BCR-ABL signalling, cleaved-PARP, a
hallmark of apoptosis was increased as a response to the
Imatinib treatment (Figure 2A). We next tested whether
Imatinib could induce PRL-3 protein down-regulation in
BaF3 murine hematopoietic cells engineered to express
either wild-type, or the Imatinib resistant T315I mutant
P210 BCR-ABL. As expected, the expression of p-CrkL,
p-STAT3 and PRL-3 was down-regulated in a dose-
dependent manner in the imatinib sensitive P210 WTarrow cells. (A) The relative expression level of PRL-3 in a gene
L-3 transcript were indicated as CML, BP (blast phase)-CML, small cell
different cancer types is available on European Bioinformatics Institute
les, untransfected parental BaF3 cells, CML cell lines and primary CML
ntrol. More details were described in Additional file 1.
Figure 2 Involvement of PRL-3 in CML response to Imatinib and CML proliferation and self-renewal. (A) K562 and KCL-22 cells were
treated with Imatinib 0 (vehicle control), 0.2 and 1 μM for 48 h. Cells were harvested and followed by Western blot analysis of a panel of proteins
shown. (B) P210 WT and P210 T315I cells were treated with either vehicle control or various concentrations of Imatinib as indicated for 48 h. Cell
lysates were used for Western blot analysis of proteins as indicated. In both (A) and (B), β-actin was used as a loading control. Densitometric
analysis was performed using Amersham Image Scanner with LabScan ImageQuant TL Software.
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was resistant to Imatinib even at high doses (10 μM) as
indicated by no change in p-CrkL. In this resistant cell
line, PRL-3 was not downregulated but rather its level
increased at higher doses of Imatinib (Figure 2B). Sur-
prisingly, p-STAT5 expression was almost completely
abolished in both P210 WT and p210 T315I cells upon
exposure to Imatinib (Figure 2B). On the other hand,
the down-regulation of PRL-3 correlated with the inhib-
ition of STAT3. Consistent with inhibition of BCR-ABL,
increased PARP cleavage fragment was observed in cells
sensitive to Imatinib (K652, P210 WT), but not in resist-
ant cells (P210 T315I) (Figure 2B). In addition to theFigure 3 Effect of silencing BCR-ABL fusion gene and STAT3 on PRL-3
PCR in K562 cells transfected with b3a2_1 siRNA and non-targeting contro
siRNA or NC siRNA together with pmaxGFP (Lonza, Switzerland) as an indic
used as recommended by the manufacturer (Lonza). The transfection effica
sequences, siRNA sequences and qRT-PCR methods were described as Sch
and PRL-3 gene expression in K562 cells transfected with STAT3 siRNA (San
Nucleofection device as described in (A). The primer sequences of STAT3 a
5’-AGCGGCTATA CTGCTGGTCAATCT-3 (antisense).STAT pathways, PI3K/AKT and MAPK/ERK signalling
pathways were also downstream of BCR-ABL signalling
and may contribute to the transformation of CML cells
[7]. However, inhibition of these two pathways did not
correlate with the down-regulation of PRL-3 protein in
the P210 and K562 cells (Additional file 2). Taken
together, these data suggest PRL-3 is downstream of
BCR-ABL mainly through the STAT pathway in CML.
Silencing BCR-ABL fusion gene or STAT3
decreased PRL-3 expression
To further confirm that the downregulation of PRL-3 is
not due to off-target effect of Imatinib, we used smallexpression. (A) Quantification of BCR-ABL and PRL-3 mRNA by qRT-
l (NC) siRNA. Two million cells were nucleofected with 30 nM b3a2_1
ator of transfection efficacy. The solution V and program T-016 were
cy was about 80%. RNAs were extracted 24 h after transfection. Primer
err et al. [24] and Zhou et al. [19]. (B) qRT-PCR quantification of STAT3
ta Cruz Biotechnologies, Inc., CA, USA) and NC siRNA in a
re as following: 5’-AGGATGGCCCAATGGAATCAGCTA-3’ (sense) and
Figure 4 Functional consequences of silencing PRL-3 in CML cells. (A) The mRNA expressions of PRL-3 and β-actin were analyzed RT-PCR in
K562-shRNA-Scramble (shC) and K562-shRNA-PRL-3 (shP) transduced cells (i). P.D. stands for primer dimer (i). Cell proliferation curves were
constructed by the total viable cells in ShC- and ShP-K562 cells cultured over 8 days. Cell proliferation and viability were determined by trypan
blue counting in every other day. Results represent the mean ± SD of triplicates (ii). Colony Forming Unit (CFU) assay of in ShC- and ShP-K562
cells. The experiments were duplicated. The upper panel of images was taken by a Canon EOS40D camera and the lower panel of pictures was
captured in 4 × 10 magnification field under an invert microscopy. The experiments were duplicated and representative pictures were presented
(iii). (iv) Comparison of tumor formation capacity in mouse xenograft models between K562-shC and K562-shP cells. (v) Average tumor weight of
three K562-shC tumors. Bar indicates standard deviation (SD). (B) P210 WT and T315I cells were nucleofected using the cell line solution V (Lonza),
program X-001 and nontargeting (NC) or mouse PRL-3 siRNA (Santa Cruz Biotechnology, Inc.). After 24 h, cells were subjected to conventional
RT-PCR and qRT-PCR analysis of PRL-3 expression or MTS assays. Cell proliferation assessments in untreated, Imatinib-treated (5, 10 μM) P210 T315I
cells transfected with either nontargeting (NC) or mouse PRL-3 siRNA for 48 h and determined by MTS assay. Results were presented the mean ±
SD of 3 independent experiments. Significant value *p < 0.05 and **p < 0.01.
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BCR-ABL fusion gene as reported by Scherr et al [24].
qRT-PCR analysis confirmed the expression of PRL-3
gene was decreased approximate 80% in b3a2_1 siRNA
transfected K562 cells, in parallel with reduction of
BCR-ABL fusion genes (Figure 3A) confirming that
PRL-3 is downstream of BCR-ABL signalling. To assess
the specific role of STAT3 in upstream regulation of
PRL-3, we decreased STAT3 mRNA by using siRNA in a
Nucelofection device. qRT-PCR showed that the expres-
sion of PRL-3 was reduced in STAT3 siRNA expressing
K562 cells compared with the control (NC) siRNA
expressing K562 cells (Figure 3B). These results support
the BCR-ABL and STAT3 are specific upstream regula-
tors of PRL-3 signalling.PRL-3 is involved in CML proliferation, self-
renewal, tumorigenic capacity and drug response
To assess the functional effect of PRL-3 in CML, we
knocked down PRL-3 using short-hairpin RNA (shRNA).
RT-PCR analysis showed that shRNA-PRL-3 transduced
K562 cells (K562-shP) demonstrated significantly reduced
PRL-3 mRNA levels as compared to shRNA-scramble
control transduced cells (K562-shC) (Figure 4Ai). K562-
shP cells proliferated as much as 2-fold slower than
K562-shC at day 8 (p < 0.001) (Figure 4Aii). K562-shP cells
also showed significantly impaired colony generating
capacity, an indicator of self-renewal capacity, by 3-fold
compared to K562-shC (p< 0.001) (Figure 3Aiii). We next
evaluated the oncogenic role of PRL-3 in CML in vivo.
Three million of K562-shC and K562-shP cells were
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of NOD/SCID mice, respectively (3 mice total). After
3 weeks, only K562-shC cells developed tumors at average
size 800 mm3 (Figure 4Aiv, right side of the animals, indi-
cated by black circles) and average tumor weight was
0.967± 0.21 g (Figure 4Av). These results indicate a critical
role for PRL-3 in CML cell expansion, and self-renewal
in vitro and in vivo. To examine if PRL-3 could be a
potential therapeutic target downstream of BCR-ABL
especially in TKI resistant cells with BCR-ABL mutations,
we utilized RNAi to knock down PRL-3 expression in
P210 T315I cells. Downregulation of mouse PRL-3
(mPRL-3) was confirmed by RT-PCR (Figure 4B, left
panel) and qRT-PCR (Figure 4B, middle panel). Indeed,
while Imatinib had no effect on P210 T315I cells, mPRL-3
silencing led to significant cell death in these cells
(Figure 4B, right panel).
In summary, the present study demonstrates that
PRL-3 is upregulated in human CML cell lines, BCR-
ABL transformed cell lines and primary CML patient
samples. Interestingly, in a previous study, high expres-
sion of PRL-3 has been associated with aggressive
phenotype of BCR-ABL positive acute lymphoblastic
leukemia (ALL) [25]. This finding, together with our
results highlight that PRL-3 is a novel downstream target
of the BCR-ABL signalling pathway, and may be a novel
mediator of BCR-ABL oncogenic functions such as cell
survival and self-renewal. Suppression of PRL-3 could
provide potential opportunity for further improving anti-
CML therapy, especially in tumors with Imatinib or TKI
resistant BCR-ABL mutants.Additional files
Additional file 1: Supplementary Methods.
Additional file 2: Figure Inhibition of MAPK/ERK and PI3K/AKT
pathway activities was not correlated to down-regulation of PRL-3
protein level. (A) P210 WT and P210 T315I cells were treated with either
vehicle control or various concentrations of Imatinib as indicated for 48
h. Cell lysates were used for Western blot analysis of proteins as
indicated. (B) K562 cells were treated with Imatinib 0 (vehicle control), 0.2
and 1 μM for 48 h. Cells were harvested and followed by Western blot
analysis of a panel of proteins shown. In both (A) and (B), β-actin was
used as a loading control. MOLM-14 cell lysates were used as positive
controls for p-AKT antibody. Densitometric analysis was performed using
Amersham Image Scanner with LabScan ImageQuant TL Software.Competing interests
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